Synergistic effect of combined HIV/HCV immunogens: A combined HIV-1/HCV candidate vaccine induces a higher level of CD8+ T cell-immune responses in HLA-A2.1 mice

Current HIV Research

Volumn 5, Issue 2, 2007, Pages 211-219

  Azizi, Ali ^a,b   Ghorbani, Masoud ^a   Soare, Catalina ^a,b   Mojibian, Majid ^b   Diaz Mitoma, Francisco ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cell mediated immune responses; CpG oligodeoxynucleotide; HCV DNA Vectors; Intracellular cytokine staining; Lymphocyte proliferation assay

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DNA; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HEPATITIS C ANTIGEN; HEPATITIS C VACCINE; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 4; INTERLEUKIN 5; MINERAL OIL; MONTANIDE ISA 51; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; DNA VACCINE; HEPATITIS VACCINE; VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA VECTOR; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MONOTHERAPY; MOUSE; NONHUMAN; REVIEW; TH1 CELL; TH2 CELL; ANIMAL; ANIMAL MODEL; ARTICLE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CULTURE TECHNIQUE; CYTOLOGY; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METABOLISM; SPLEEN; VIROLOGY;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; FEMALE; GENE PRODUCTS, GAG; HEPACIVIRUS; HEPATITIS C; HIV; HLA-A2 ANTIGEN; IMMUNITY, CELLULAR; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; SPLEEN; TH1 CELLS; TH2 CELLS; VACCINES, COMBINED; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

EID: 33947607639     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780077066     Document Type: Review

References (40)

1. Alvarado EC, Leroux-Roels G. (1999). Hepatitis C immunology. Revista de Investigación Clínica. 51: 315-322.
2. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. (2002). Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Review of Vaccines. 1: 111-118.
3. Azizi A, Ghorbani M, Kryworuchko M, Aucoin S, Diaz-Mitoma F. (2005). Potency of Cell-Mediated Immune Responses to Different Combined HIV-1 Immunogens in a Humanized Murine Model. Human Vaccines. 1(4):170-176.
4. Balestra E, Aquaro S, Perno CF. (2003). HIV/HCV co-infection: the magnitude of the problem. Journal of Biological Regulators and Homeostatic Agents. 17: 138-143.
5. Beeching NJ, Clarke PD, Kitchin NF, Pirmohamed J, Veitch K, Weber F. (2004). Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine. 23: 29-35.
6. Buseyne F, McChesney M, Porrot F, Kovarik S, Guy B, Riviere Y. (1993). Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. Journal of Virology. 67: 694-702.
7. Carlos MJ, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. (2004). Impact of chronic hepatitis C on HIV-1 disease progression. HIV clinical trials. 5: 125-131.
8. Chippaux JP, Garba A, Ethevenaux C, Campagne G, de Chabalier F, Djibo S, Nicolas P, Ali H, Charrondiere M, Ryall R, Bybel M, Schuchat A. (2004). Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine. 22: 3303-3311.
9. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R. (2006). Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology. 346: 151-168.
10. Daly LM, Johnson PA, Donnelly G, Nicolson C, Robertson J, Mills KH. (2005). Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine. 23: 963-974.
11. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu JS, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF. (2005). Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. Journal of Virology. 79: 1154-1163.
12. Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, Ingerani Mercer D, Moniaga V, Moulton LH, Moulton LH, Mulholland K, Nelson C, Soemohardjo S, Steinhoff M, Widjaya A, Stoeckel P, Maynard J, Arjoso S. (2005). Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet. 365: 43-52.
13. Ghorbani M, Nass T, Azizi A, Soare C, Aucoin S, Giulivi A, Anderson DE, Diaz-Mitoma F. (2005). Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice. Viral Immunology. 18: 637-648.
14. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A. (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 356: 1800-1805.
15. Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, Chen KT, Yawetz S, Pacheco S, Davenny K, Adeniyi-Jones S, Thomas DL. (2005). Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clinical infectious diseases. 40: 859-867.
16. Hu GJ, Wang RY, Han DS, Alter HJ, Shih JW. (1999). Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine. 17: 3160-3170.
17. Ikeda-Moore Y, Tomiyama H, Miwa K, Oka S, Iwamoto A, Kaneko Y, Takiguchi, M. (1997). Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. Journal of Immunology. 159: 6242-6252.
18. Jin J, Yang J Y, Liu J, Kong YY, Wang Y, Li GD. (2002). DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV. World Journal of Gastroenterology. 8: 505-510.
19. Kim YB, Han DP, Cao C, Cho MW. (2003). Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology. 305: 124-137.
20. Kuchtey J, Chefalo PJ, Gray RC, Ramachandra L, Harding CV. (2005). Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA. Journal of Immunology. 175: 2244-2251.
21. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL. (2004). CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infection and Immunity. 72: 949-957.
22. Lasaro MO, Luiz WB, Sbrogio-Almeida ME, Nishimura LS, Guth BE, Ferreira LC. (2004). Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains. Infection and Immunity. 72: 6480-6491.
23. Lee SW, Cho JH, Lee KJ, Sung YC. (1998). Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Molecules and Cells. 8: 444-451.
24. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, Xu L, Yang ZY, Chakrabarti B, Rao SS, Schmitz JE, Montefiori DC, Barker BR, Bookstein FL, Nabel GJ. (2006). Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science. 312: 1530-1533.
25. Moss RB, Diveley J, Jensen FC, Gouveia E, Carlo DJ. (2001). Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA. Journal of Human Virology. 4: 39-43.
26. Moss RB, Diveley J, Jensen FC, Gouveia E, Savary J, Carlo DJ. (2000). HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA. Journal of Interferon and Cytokine Research. 20: 1131-1137.
27. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk L, Giulivi A, Soare C, Azizi A, Diaz-Mitoma F. (2005). Characterization of liver histopathology in a transgenic mouse model expressing genotype la hepatitis C virus core and envelope proteins 1 and 2. Journal of General Virology. 86: 2185-2196.
28. Nakamura Y, Kameoka M, Tobiume M, Kaya M, Ohki K, Yamada T, IkutaK. (1997). A chain section containing epitopes for cytotoxic T, B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein. Vaccine. 15: 489-496.
29. Netter HJ, Macnaughton TB, Woo WP, Tindle I, Gowans EJ. (2001). Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. Journal of Virology. 75: 2130-2141.
30. Newton DA, Acierno PM, Brescia FJ, Brown EA, Gattoni-Celli S. Semi-allogeneic vaccines for patients with cancer and AIDS. Journal of Immunotherapy. 25: 334-341.
31. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. (2005). Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. The Journal of infectious diseases. 191: 515-519.
32. Paoletti LC, Kennedy RC. (2002). Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3. The Journal of infectious diseases. 186: 1597-1602.
33. Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, Andrus L, Shata MT. (2005). Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. The Journal of Infectious Diseases. 192: 1701-1709.
34. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. (2005). Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Journal of Clinical Oncology. 23: 741-750.
35. Tossing G. (2005). Management of chronic hepatitis C in HIV-coinfected patients - results from the First International Workshop on HIV and Hepatitis Co-infection, 2nd-4th December 2004, Amsterdam, Netherlands. European Journal of Medical Research. 10: 43-45.
36. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A. (2003). Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. Journal of acquired immune deficiency syndromes. 33: 146-152.
37. van Asten L, Prins M. (2004). Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS. 18: 2319-2324.
38. Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A. (1999). Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine. 17: 2166-2175.
39. Ward S, Lauer G, Isba R, Walker B, Klenerman P. (2002). Cellular immune responses against hepatitis C virus: the evidence base 2002. Clinical and Experimental Immunology. 128: 195-203.
40. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA. (2006). Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. The Journal of Experimental Medicine. 203: 1249-1258.